Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
Authors:
Open Access
- 30 July 2015
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 10 (4) , 1979-1984
Abstract
The inhibition of apoptosis in cancer cells is the major pathological feature of hepatic carcinoma. Rosiglitazone (RGZ), a ligand for peroxisome proliferator-activated receptor γ (PPAR-γ), has been shown to induce apoptosis in hepatic carcinoma cells. However, the mechanism underlying this effect remains to be elucidated. The present study aimed to investigate the effect of RGZ on cell viability and apoptosis, and its mechanisms in cultured HepG2 cells using MTT assay, flow cytometry and western blotting. The results revealed that treatment with RGZ may attenuate HepG2 cell viability and induce the apoptosis of the cells. The mechanism of RGZ-induced apoptosis involves an increase in the level of activated PPAR-γ (p-PPAR-γ) and a decrease in p85 and Akt expression. In addition, the PPAR-γ antagonist GW9662 suppressed the effect of RGZ in the HepG2 cells. Taken together, the results suggest that RGZ induces the apoptosis of HepG2 cells through the activation of PPAR-γ, suppressing the activation of the PI3K/Akt signaling pathway. Such mechanisms may contribute to the favorable effects of treatment using RGZ in HepG2 cells.Keywords
This publication has 28 references indexed in Scilit:
- Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menaceJournal of Hepatology, 2012
- Hepatocellular Carcinoma: Focus on Different Aspects of ManagementISRN Oncology, 2012
- Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implicationsWorld Journal of Virology, 2012
- Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinomaCancer Letters, 2011
- PI3Kβ Plays a Critical Role in Neutrophil Activation by Immune ComplexesScience Signaling, 2011
- A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathwayCellular Microbiology, 2009
- Compound 48, a novel dual PPAR α/γ ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinibLeukemia Research, 2009
- Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone– Induced Apoptosis in Leukemia K562 Cells and Its Mechanisms of ActionInternational Journal of Toxicology, 2009
- PPARβ/δ agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-κB signalsAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- The role of PI3K in immune cellsNature Immunology, 2003